Analysis of Potential Genotoxic Impurities in Active Pharmaceutical Ingredients

Importance of the Topic

Synthesis of active pharmaceutical ingredients often involves sulfonic acids that can form genotoxic sulfonic acid esters as byproducts. Detecting these potential genotoxic impurities (PGIs) at trace levels is critical to ensure patient safety and regulatory compliance in pharmaceutical manufacturing.

Objectives and Overview

This study demonstrates a sensitive GC-MS method for simultaneous screening and quantification of methanesulfonate, benzenesulfonate, and p-toluenesulfonate esters in API matrices. The goal is to achieve reliable detection at ng/mL levels and provide a robust workflow for quality control laboratories.

Used Instrumentation

• Gas Chromatograph-Mass Spectrometer: Shimadzu GCMS-QP2010 Ultra
• Capillary Column: Rtx-200, 30 m × 0.25 mm I.D., 0.25 μm film thickness
• Injection Liner: Deactivated split liner with wool

Methodology

FASST mode (Fast Automated Scan/SIM) was employed to collect full-scan (m/z 40–330) and selected ion monitoring data simultaneously. Key GC parameters include split injection at 280 °C, helium carrier gas at 40 cm/s, and oven program from 70 °C (2 min) to 320 °C at 15 °C/min (3 min hold). MS settings feature an interface temperature of 280 °C, ion source at 230 °C, solvent cut time of 1.5 min, high-sensitivity tuning, scan event time of 0.1 s, and SIM event time of 0.3 s. SIM transitions were optimized for each ester to enhance selectivity and sensitivity.

Main Results and Discussion

Baseline separation of twelve sulfonic acid esters was achieved with retention times ranging from 5.25 min to 12.49 min. Total ion current chromatograms confirmed distinct elution of methanesulfonate, benzenesulfonate, and p-toluenesulfonate esters; mass chromatograms validated characteristic ions for each compound. Quantitation at a standard concentration of 10 ng/mL (equivalent to 1 ng/mg in APIs after 100× dilution) showed high recovery (~100 %) and reproducibility, supporting method robustness.

Benefits and Practical Applications

• Rapid, concurrent screening of multiple PGIs in a single analytical run
• Low detection limits aligned with regulatory safety thresholds
• Minimal sample preparation and high sample throughput
• Applicable across diverse API matrices for routine quality control

Future Trends and Possibilities

Advances in high-resolution mass spectrometry, automated sample introduction, and miniaturized GC systems will further enhance sensitivity and robustness. Integration with regulatory databases and AI-driven data analysis platforms may streamline PGI profiling, accelerate method development, and support real-time quality monitoring.

Conclusion

The described GCMS-QP2010 Ultra FASST method delivers a reliable, sensitive, and efficient solution for detecting genotoxic sulfonic acid esters in active pharmaceutical ingredients. Its implementation supports stringent quality assurance and compliance with regulatory guidelines.

References

• Shimadzu Corporation. Analysis of Potential Genotoxic Impurities in Active Pharmaceutical Ingredients. Application Note LAAN-J-MS-E018B, Third Edition, November 2016.